Literature DB >> 22699526

The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients.

Hanna Maria Fuglø1, Simon Møller Jørgensen, Annika Loft, Dorrit Hovgaard, Michael M Petersen.   

Abstract

PURPOSE: To evaluate the feasibility of (18)F-FDG PET/CT for initial assessment in high-grade bone sarcomas (BS) and soft tissue sarcomas (STS).
METHODS: During the years 2001-2010, 89 patients (30 BS, 59 STS) referred for further evaluation and surgical treatment of a high-grade BS or STS also had a PET/CT scan performed for staging preoperatively (n = 68) or within 1 month of surgery (n = 21). Metastatic lesions suggested on the PET/CT scan were confirmed or rejected by histological evaluation, by additional imaging or by follow-up. In 68 patients (28 BS, 40 STS) the relationship between the maximal standardized uptake value (SUVmax) of the primary tumour and survival was examined.
RESULTS: The PET/CT scan suggested the presence of 13 metastatic lesions in BS patients (5 lymph node, 8 distant) and 21 metastatic lesions (6 lymph node, 15 distant) in STS patients. The calculated sensitivity (SE) and specificity (SP) were 95 % and 96 % for detection of distant metastases, and the predictive value (PV) of a positive or a negative test was 87 % and 98 %, respectively. SE and SP were 100 % and 90 % for detection of lymph node metastases, and the PV of a positive or a negative test was 27 % and 100 %, respectively. The 5-year survival was 81 % among patients with SUVmax below the median value (≤ 10), but was 33 % among those with SUVmax >10.
CONCLUSION: FDG PET/CT for the initial assessment of patients with high-grade BS or STS was feasible with high SE and SP, but in those with lymph node metastases the PV of a positive test was low. The SUVmax of the primary tumour was a strong prognostic factor for survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22699526     DOI: 10.1007/s00259-012-2159-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  27 in total

1.  Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.

Authors:  Matthias H M Schwarzbach; Ulf Hinz; Antonia Dimitrakopoulou-Strauss; Frank Willeke; Servando Cardona; Gunhild Mechtersheimer; Thomas Lehnert; Ludwig G Strauss; Christian Herfarth; Markus W Büchler
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

2.  PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients.

Authors:  A K Berthelsen; S Holm; A Loft; T L Klausen; F Andersen; L Højgaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-21       Impact factor: 9.236

3.  Survival of adult patients with cancer of soft tissues or bone in Europe. EUROCARE Working Group.

Authors:  H H Storm
Journal:  Eur J Cancer       Date:  1998-12       Impact factor: 9.162

4.  Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group.

Authors:  J M Coindre; P Terrier; L Guillou; V Le Doussal; F Collin; D Ranchère; X Sastre; M O Vilain; F Bonichon; B N'Guyen Bui
Journal:  Cancer       Date:  2001-05-15       Impact factor: 6.860

5.  FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases.

Authors:  Mathieu Charest; Marc Hickeson; Robert Lisbona; Javier-A Novales-Diaz; Vilma Derbekyan; Robert E Turcotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

6.  Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.

Authors:  Scott M Schuetze; Brian P Rubin; Cheryl Vernon; Douglas S Hawkins; James D Bruckner; Ernest U Conrad; Janet F Eary
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

7.  A system for the surgical staging of musculoskeletal sarcoma.

Authors:  W F Enneking; S S Spanier; M A Goodman
Journal:  Clin Orthop Relat Res       Date:  1980 Nov-Dec       Impact factor: 4.176

Review 8.  Sarcoma.

Authors:  Keith M Skubitz; David R D'Adamo
Journal:  Mayo Clin Proc       Date:  2007-11       Impact factor: 7.616

9.  Diagnostic value of PET/CT for the staging and restaging of pediatric tumors.

Authors:  Margit Kleis; Heike Daldrup-Link; Katherine Matthay; Robert Goldsby; Ying Lu; Tibor Schuster; Carole Schreck; Philip W Chu; Randall A Hawkins; Benjamin L Franc
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-22       Impact factor: 9.236

10.  Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.

Authors:  Thomas Völker; Timm Denecke; Ingo Steffen; Daniel Misch; Stefan Schönberger; Michail Plotkin; Juri Ruf; Christian Furth; Brigitte Stöver; Hubertus Hautzel; Günter Henze; Holger Amthauer
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

View more
  28 in total

1.  FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up.

Authors:  Austin Ostermeier; M Beth McCarville; Fariba Navid; Scott E Snyder; Barry L Shulkin
Journal:  Pediatr Radiol       Date:  2015-02-27

2.  Hybrid PET/MR imaging in two sarcoma patients - clinical benefits and implications for future trials.

Authors:  Sasan Partovi; Andres A Kohan; Lisa Zipp; Peter Faulhaber; Christos Kosmas; Pablo R Ros; Mark R Robbin
Journal:  Int J Clin Exp Med       Date:  2014-03-15

3.  Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma.

Authors:  Eun-Seok Choi; Seung-Gyun Ha; Han-Soo Kim; Jae Hong Ha; Jin Chul Paeng; Ilkyu Han
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-24       Impact factor: 9.236

Review 4.  Local recurrence of soft-tissue sarcoma: issues in imaging surveillance strategy.

Authors:  Nisreen S Ezuddin; Juan Pretell-Mazzini; Raphael L Yechieli; Darcy A Kerr; Breelyn A Wilky; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2018-05-21       Impact factor: 2.199

5.  The Role of (18)F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma.

Authors:  Kyoung Jin Chang; Ilhan Lim; Joon Yeun Park; A Ra Jo; Chang Bae Kong; Won Seok Song; Wan Hyeong Jo; Soo Yong Lee; Jae Soo Koh; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Nucl Med Mol Imaging       Date:  2014-10-30

6.  Pretreatment tumor SUVmax predicts disease-specific and overall survival in patients with head and neck soft tissue sarcoma.

Authors:  Seung Cheol Ha; Jungsu S Oh; Jong-Lyel Roh; Hyojeong Moon; Jae Seung Kim; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-23       Impact factor: 9.236

7.  Positron emission tomography/computed tomography for osseous and soft tissue sarcomas: A systematic review of the literature and meta-analysis.

Authors:  Aikeremujiang Muheremu; Junyi Ma; Aierken Amudong; Yong Ma; Maimaitiaili Niyazi; Yong Ou; Yuan Ma
Journal:  Mol Clin Oncol       Date:  2017-07-18

8.  Prognostic value of 18F-FDG PET/CT in patients with soft tissue sarcoma: comparisons between metabolic parameters.

Authors:  Sun-pyo Hong; Seung Eun Lee; Yoon-La Choi; Sung Wook Seo; Ki-Sun Sung; Hong Hoe Koo; Joon Young Choi
Journal:  Skeletal Radiol       Date:  2014-02-15       Impact factor: 2.199

Review 9.  Applications of PET-MRI in musculoskeletal disease.

Authors:  Feliks Kogan; Stephen M Broski; Daehyun Yoon; Garry E Gold
Journal:  J Magn Reson Imaging       Date:  2018-07       Impact factor: 4.813

10.  The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma.

Authors:  Natale Quartuccio; Giorgio Treglia; Marco Salsano; Maria Vittoria Mattoli; Barbara Muoio; Arnoldo Piccardo; Egesta Lopci; Angelina Cistaro
Journal:  Radiol Oncol       Date:  2013-05-21       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.